Abstract
The podocytes within the glomeruli of the kidney maintain the filtration barrier by forming interdigitating foot processes with intervening slit diaphragms, disruption in which results in proteinuria. Studies into human podocytopathies to date have employed primary or immortalised podocyte cell lines cultured in 2D. Here we compare 3D human glomeruli sieved from induced pluripotent stem cell-derived kidney organoids with conditionally immortalised human podocyte cell lines, revealing improved podocyte-specific gene expression, maintenance in vitro of polarised protein localisation and an improved glomerular basement membrane matrisome compared to 2D cultures. Organoid-derived glomeruli retain marker expression in culture for 96 h, proving amenable to toxicity screening. In addition, 3D organoid glomeruli from a congenital nephrotic syndrome patient with compound heterozygous NPHS1 mutations reveal reduced protein levels of both NEPHRIN and PODOCIN. Hence, human iPSC-derived organoid glomeruli represent an accessible approach to the in vitro modelling of human podocytopathies and screening for podocyte toxicity.
Original language | English |
---|---|
Pages (from-to) | 5167 |
Number of pages | 1 |
Journal | Nature Communications |
Volume | 9 |
Issue number | 1 |
Early online date | 4 Dec 2018 |
DOIs | |
Publication status | Published - 4 Dec 2018 |
Keywords
- Cell Culture Techniques/methods
- Cell Line
- Cells, Cultured
- Collagen/metabolism
- Drug Evaluation, Preclinical
- Female
- Gene Expression
- Gene Expression Profiling
- Humans
- Immunohistochemistry
- Induced Pluripotent Stem Cells/cytology
- Insulin/pharmacology
- Intracellular Signaling Peptides and Proteins/genetics
- Kidney
- Kidney Glomerulus/cytology
- Laminin/metabolism
- Membrane Proteins/genetics
- Mutation
- Nephrotic Syndrome/pathology
- Organoids/cytology
- Podocytes/cytology
- Sequence Analysis
- Sequence Analysis, RNA
- Stem Cells
Fingerprint
Dive into the research topics of '3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening'. Together they form a unique fingerprint.Equipment
-
Biological Mass Spectrometry (BioMS) Facility
Knight, D. (Core Facility Lead), Warwood, S. (Senior Technical Specialist), Selley, J. (Technical Specialist), Taylor, G. (Technical Specialist), Fullwood, P. (Technical Specialist), Keevill, E.-J. (Senior Technician) & Allsey, J. (Technician)
FBMH Platform Sciences, Enabling Technologies & InfrastructureFacility/equipment: Facility